Immunome (IMNM) Stock Forecast & Price Target

Immunome is attractive because varegacestat has already shown strong Phase 3 RINGSIDE efficacy in desmoid tumors, including an 84% reduction in risk of progression or death, a 56% confirmed ORR versus 9% for placebo, and statistically significant pain improvement, supporting a potential 2027 launch and ~$66M first-year revenue estimate. Beyond that, IM-1021 could validate the company’s HC74 payload strategy if it shows activity across heavily pretreated lymphoma patients, including DLBCL and follicular lymphoma, because durable responses, tolerability, and activity after prior Topo1 or MMAE exposure would strengthen the case for differentiated ADC design. The balance sheet also supports execution, with $520MM in cash, cash equivalents, and marketable securities at 2Q26 expected to fund operations into 2028, while multiple 2026 catalysts across IM-1021, IM-1617, IM-3050, IM-1340, and IM-1335 create additional upside beyond varegacestat.

Immunome is a high-risk early-development biotech whose value depends on unproven clinical translation across multiple programs, especially IM-1021 and 177Lu-FAP, where efficacy, safety, and biomarker selection remain unresolved. The cited concern that ROR1 RNA may not reliably reflect surface protein, along with the possibility of antigen downregulation and prior failures in solid tumors with zilovertamab vedotin, weakens confidence that the platform can overcome resistance or justify broad investment. Financially, the company still faces the need for additional equity financing, while its 12-month valuation framework assumes FY38 GAAP EPS of $6.04 and an NPV of $38.4/share, highlighting how far away the thesis is from durable commercial proof.